Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003–2011)

Annals of Surgical Oncology

Volumn 22, Issue 7, 2015, Pages 2120-2126

  Cavanaugh Hussey, Margaret W ^a   Mu, Euphemia W ^b   Kang, Sewon ^c   Balch, Charles M ^d   Wang, Timothy ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; GERIATRIC DISORDER; GERIATRIC SURGERY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SEX DIFFERENCE; SURVIVAL RATE; TUMOR VOLUME; VERY ELDERLY; AGE; CANCER REGISTRY; CANCER STAGING; INCIDENCE; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84930485563     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4538-8     Document Type: Article

References (27)

1. Austin PF, Cruse CW, Lyman G, Schroer K, Glass F, Reintgen DS. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol. 1994;1(6):487–94.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001;19(16):3622–34.
3. Balch, CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–9.
4. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112(8):1795–804.
5. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579–85.
6. Thompson JF, Soon SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer. J Clin Oncol. 2011;29(16):2199–205.
7. Chao C, Martin RC 2nd, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol. 2004;11(3):259–64.
8. Macdonald, JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538–43.
9. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100–8.
10. Page AJ, Li A, Hestley A, Murray D, Carlson GW, Delman KA. Increasing age is associated with worse prognostic factors and increased distant recurrences despite fewer sentinel lymph node positives in melanoma. Int J Surg Oncol. 2012;456987.
11. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91(12):2401–8.
12. Balch CM, Thompson JF, Gershenwald JE, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann SurgOncol. 2014;21(4):1075–81.
13. He W, Sengupta M, Velkoff VA, DeBarros KA. 65+ in the United States. U.S. Census Bureau. 2005. http://www.census.gov/prod/2006pubs/p.23-209.pdf. Accessed 15 July 2012.
14. Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.
15. Seer Databases. Overview page. http://seer.cancer.gov/about/overview.html. Accessed 25 April 2014.
16. Lange JR, Kang S, Balch CM. Melanoma in the older patient: measuring frailty as an index of survival (2011). Ann Surg Oncol. 2011;18(13):3531–2.
17. Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol. 2010;7(3):148–52.
18. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol. 2010;17(6):1475–7.
19. Soong SJ, Ding S, Coit DG, Balch CM, Gershenwald JE, Thompson JF, Gimotty P. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17(8):2006–14.
20. Varani J, Warner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol. 2000;114(3):480–6.
21. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, Morton DL. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16(6):1548–52.
22. Pan WR, Suami H, Taylor GI. Senile changes in human lymph nodes. Lymphat Res Biol. 2008;6(2):77–83.
23. Pawlick, TM, Ross M, Johnson M, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587–96.
24. Leppänen E, Leidenius M, Krogerus L, von Smitten K. The effect of patient and tumour characteristics on visualization of sentinel nodes after a single intratumoural injection of Tc 99m labelled human albumin colloid in breast cancer. Eur J Surg Oncol. 2002;28(8):821–6.
25. Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012;30(2):126–32.
26. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare Database: applications and limitations. Med Care. 2002;40(8 Suppl):IV-19-25.
27. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Epidemiological support for melanoma heterogeneity Using the Surveillance, Epidemiology, and End Results Program. JInvest Dermatol. 2008;128(5):1340–2.